嵌合抗原受体 T 细胞疗法中的 B 细胞靶向：是 CAR T 细胞功能的副作用还是驱动因素？
B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?
机构信息
Graduate Group in Genomics and Computational Biology, University of Pennsylvania, Philadelphia, PA, USA.
Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
出版信息
Sci Transl Med. 2022 Jun 22;14(650):eabn3353. doi: 10.1126/scitranslmed.abn3353.
Abstract
Chimeric antigen receptor (CAR) T cell therapies targeting CD19 and CD22 have been successful for treating B cell cancers, but CAR T cells targeting non-B cell cancers remain unsuccessful. We propose that rather than being strictly a side effect of therapy, the large number of CAR interactions with normal B cells may be a key contributor to clinical CAR T cell responses.
摘要
嵌合抗原受体 (CAR) T 细胞疗法靶向 CD19 和 CD22 已成功用于治疗 B 细胞癌症，但靶向非 B 细胞癌症的 CAR T 细胞仍不成功。我们提出，CAR 与正常 B 细胞的大量相互作用可能是临床 CAR T 细胞反应的关键因素，而不是严格意义上的治疗副作用。
相似文献
1
B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?嵌合抗原受体 T 细胞疗法中的 B 细胞靶向：是 CAR T 细胞功能的副作用还是驱动因素？
Sci Transl Med. 2022 Jun 22;14(650):eabn3353. doi: 10.1126/scitranslmed.abn3353.
2
Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.CD22/CD19 嵌合抗原受体 T 细胞疗法治疗累及胃肠道的复发/难治性侵袭性 B 细胞淋巴瘤患者的疗效和毒性。
Cytotherapy. 2020 Mar;22(3):166-171. doi: 10.1016/j.jcyt.2020.01.008. Epub 2020 Feb 13.
3
Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.嵌合抗原受体 T 细胞疗法治疗小儿 B-ALL：缩小早期和长期结局之间的差距。
Front Immunol. 2020 Aug 11;11:1985. doi: 10.3389/fimmu.2020.01985. eCollection 2020.
4
Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.嵌合抗原受体（CAR）T 细胞治疗 B 细胞恶性肿瘤患者的疗效和安全性的系统评价和荟萃分析方案。
Syst Rev. 2021 Jan 21;10(1):35. doi: 10.1186/s13643-021-01588-7.
5
Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells.纳米颗粒在细胞治疗时代的前景与局限：以靶向 CD19 的嵌合抗原受体（CAR）修饰 T 细胞为例。
Int J Pharm. 2017 Nov 5;532(2):813-824. doi: 10.1016/j.ijpharm.2017.07.075. Epub 2017 Jul 29.
6
Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.在一项针对小儿急性淋巴细胞白血病的 I 期研究中，证明了移植的嵌合抗原受体修饰的 CD19 特异性 T 细胞具有持久的抗 CD19 活性。
Hematol Oncol. 2019 Dec;37(5):601-608. doi: 10.1002/hon.2672. Epub 2019 Sep 15.
7
Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models.三特异性 CD19-CD20-CD22 双靶点 CAR-T 细胞在临床前模型中消除抗原异质性 B 细胞肿瘤。
Sci Transl Med. 2021 Mar 24;13(586). doi: 10.1126/scitranslmed.abc6401.
8
[In vitro studies on the transfer of CAR into leukemia cells due to their residue in the autologous CAR-T cell preparation system for acute B-cell acute lymphoblastic leukemia].[关于急性B淋巴细胞白血病自体嵌合抗原受体T细胞制备系统中CAR因残留而转移至白血病细胞的体外研究]
Zhonghua Xue Ye Xue Za Zhi. 2021 Feb 14;42(2):140-145. doi: 10.3760/cma.j.issn.0253-2727.2021.02.009.
9
In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.体内第二代与第三代 CD19 特异性 CAR-T 细胞在 B 细胞非霍奇金淋巴瘤中的命运和活性。
Mol Ther. 2018 Dec 5;26(12):2727-2737. doi: 10.1016/j.ymthe.2018.09.009. Epub 2018 Sep 13.
10
[Chimeric antigen receptor T-cell therapy for multiple myeloma].嵌合抗原受体T细胞疗法治疗多发性骨髓瘤
Rinsho Ketsueki. 2018;59(10):2189-2194. doi: 10.11406/rinketsu.59.2189.
引用本文的文献
1
Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups.溶瘤病毒和嵌合抗原受体T细胞基因治疗进展及治疗相关分组
Curr Issues Mol Biol. 2025 Apr 10;47(4):268. doi: 10.3390/cimb47040268.
2
Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach.新型靶向PAP的CAR-T疗法通过偶联CAR方法增强抗肿瘤疗效。
J Immunother Cancer. 2025 May 31;13(5):e011238. doi: 10.1136/jitc-2024-011238.
3
Robust CAR T-cell expansion and superior outcomes in DLBCL patients in complete response at infusion.在输注时达到完全缓解的弥漫性大B细胞淋巴瘤（DLBCL）患者中，CAR T细胞强劲扩增且预后更佳。
Br J Haematol. 2025 Jul;207(1):180-188. doi: 10.1111/bjh.20186. Epub 2025 May 25.
4
Targeting inflammation with chimeric antigen receptor macrophages using a signal switch.利用信号开关，通过嵌合抗原受体巨噬细胞靶向炎症。
Nat Biomed Eng. 2025 May 7. doi: 10.1038/s41551-025-01387-8.
5
Harnessing myeloid cells in cancer.利用癌症中的髓样细胞。
Mol Cancer. 2025 Mar 6;24(1):69. doi: 10.1186/s12943-025-02249-2.
6
Development of multivalent CAR T cells as dual immunotherapy and conditioning agents.多价嵌合抗原受体T细胞作为双重免疫疗法和预处理剂的开发。
Mol Ther Oncol. 2025 Jan 30;33(1):200944. doi: 10.1016/j.omton.2025.200944. eCollection 2025 Mar 20.
7
Oncolytic Viruses as Reliable Adjuvants in CAR-T Cell Therapy for Solid Tumors.溶瘤病毒在 CAR-T 细胞治疗实体瘤中的可靠佐剂作用。
Int J Mol Sci. 2024 Oct 16;25(20):11127. doi: 10.3390/ijms252011127.
8
Application of combined ablation and immunotherapy in NSCLC and liver cancer: Current status and future prospects.联合消融与免疫疗法在非小细胞肺癌和肝癌中的应用：现状与未来展望
Heliyon. 2024 Aug 14;10(16):e36388. doi: 10.1016/j.heliyon.2024.e36388. eCollection 2024 Aug 30.
9
Efficient Chimeric Antigen Receptor T-Cell Generation Starting with Leukoreduction System Chambers of Thrombocyte Apheresis Sets.从血小板单采装置的白细胞滤除系统腔室开始高效生成嵌合抗原受体T细胞。
Transfus Med Hemother. 2023 Aug 30;51(2):111-118. doi: 10.1159/000532130. eCollection 2024 Apr.
10
Advances in the study of B cells in renal ischemia-reperfusion injury.肾缺血再灌注损伤中 B 细胞研究进展。
Front Immunol. 2023 Nov 1;14:1216094. doi: 10.3389/fimmu.2023.1216094. eCollection 2023.
本文引用的文献
1
Decade-long leukaemia remissions with persistence of CD4 CAR T cells.长达十年的白血病缓解期与 CD4 CAR T 细胞的持续存在。
Nature. 2022 Feb;602(7897):503-509. doi: 10.1038/s41586-021-04390-6. Epub 2022 Feb 2.
2
Perfect adaptation of CD8 T cell responses to constant antigen input over a wide range of affinities is overcome by costimulation.共刺激作用克服了 CD8 T 细胞对广泛亲和力范围内恒定抗原输入的完美适应。
Sci Signal. 2021 Jan 19;14(666):eaay9363. doi: 10.1126/scisignal.aay9363. Epub 2021 Jul 15.
3
The role of exhaustion in CAR T cell therapy.耗竭在 CAR T 细胞治疗中的作用。
Cancer Cell. 2021 Jul 12;39(7):885-888. doi: 10.1016/j.ccell.2021.06.012.
4
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease.嵌合抗原受体 T 细胞（CAR-T）治疗使伴有微小残留病的 B 细胞急性淋巴细胞白血病患者获得持久缓解。
Cancer Immunol Immunother. 2021 Dec;70(12):3501-3511. doi: 10.1007/s00262-021-02941-4. Epub 2021 Apr 25.
5
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.不依赖抗原的激活增强了4-1BB共刺激的CD22嵌合抗原受体T细胞的疗效。
Nat Med. 2021 May;27(5):842-850. doi: 10.1038/s41591-021-01326-5. Epub 2021 Apr 22.
6
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling.短暂休息通过表观遗传重塑恢复衰竭的 CAR-T 细胞的功能。
Science. 2021 Apr 2;372(6537). doi: 10.1126/science.aba1786.
7
Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.抗 CD19 CAR T 细胞能有效地重定向以杀死实体瘤细胞。
PLoS One. 2021 Mar 18;16(3):e0247701. doi: 10.1371/journal.pone.0247701. eCollection 2021.
8
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide.基于来那度胺调控的可逆转 ON/OFF 开关嵌合抗原受体
Sci Transl Med. 2021 Jan 6;13(575). doi: 10.1126/scitranslmed.abb6295.
9
Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors.使用溶瘤病毒将嵌合抗原受体（CAR）靶点递送至实体瘤的有效联合免疫疗法。
Sci Transl Med. 2020 Sep 2;12(559). doi: 10.1126/scitranslmed.aaz1863.
10
How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.我如何预防接受针对 B 细胞恶性肿瘤的 CD19 靶向嵌合抗原受体 T 细胞治疗的患者感染。
Blood. 2020 Aug 20;136(8):925-935. doi: 10.1182/blood.2019004000.
Zotero 插件